| Health / Medical Topics |
PR1 Leukemia Peptide Vaccine
A cancer vaccine containing PR1, a 9 amino-acid human leukocyte antigen (HLA)-A2 restricted peptide derived from proteinase 3, with potential immunotherapeutic activity. Vaccination with PR1 leukemia peptide vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells expressing proteinase 3, resulting in tumor cell lysis. Often overexpressed in leukemic cells, proteinase 3 is a serine proteinase that activates progelatinase A and is involved in angiogenesis and metastasis. (NCI Thesaurus)
YOU MAY ALSO LIKE
Describes cells that have a protein to which the hormone progesterone will bind. Cancer cells that are PR+ need progesterone to grow…
A synthetic form of the ras peptide containing a point mutation at position 12 (glycine to valine). Vaccines using mutant ras peptides…
A synthetic form of the ras peptide containing a point mutation at position 13 (glycine to asparagine). Vaccines using mutant ras peptides…
A tumor-specific peptide encoded by patient-specific mutant p53 oncogene with potential immunostimulatory properties. The peptide (LPTGQDL) contains a frame shift mutation at…
A substance being studied in the treatment of cancer. PR-104 becomes active when cancer cells don’t receive enough oxygen. It may kill…
Describes cells that do not have a protein to which the hormone progesterone will bind. Cancer cells that are PR- do not…
